ReviewJournal of diabetes and metabolic disorders2025
Revolutionizing diabetic foot ulcer treatment: phage therapy as a next-generation antimicrobial approach- a review on breaking the cycle of resistance.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innate immune recognition and immunomodulatory effects of bacteriophages: implications for phage therapy.Frontiers in immunology · 2026Review
- Bacterial profile and antimicrobial resistance patterns of infected diabetic foot ulcers in low- and middle-income countries: a systematic review and meta‑analysis.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFUs) are a major complication of diabetes, impacting approximately one-third of diabetic patients worldwide. Treating DFUs has become increasingly difficult due to the rise of multidrug-resistant bacteria like Results: Evidence from laboratory studies, animal models, and early clinical research shows that phage therapy is effective in targeting drug-resistant bacteria involved in DFUs. Phages offer several advantages, including their ability to specifically target harmful bacteria, break down biofilms, and multiply at infection sites. These characteristics make them a promising tool for treating chronic, non-healing wounds. Conclusion: Bacteriophage therapy represents a cutting-edge strategy for managing DFUs, particularly in cases where conventional antibiotics fail. By utilizing the natural antibacterial properties of phages, this approach could lead to more personalized and precise wound care, potentially transforming the way chronic diabetic ulcers are treated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.